Metropolitan Life Insurance Co. NY Purchases 41,919 Shares of TransEnterix, Inc. (TRXC)
Metropolitan Life Insurance Co. NY raised its position in TransEnterix, Inc. (NYSEAMERICAN:TRXC) by 356.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,674 shares of the medical instruments supplier’s stock after purchasing an additional 41,919 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in TransEnterix were worth $121,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of TransEnterix in the fourth quarter worth about $29,000. Oppenheimer & Co. Inc. lifted its position in shares of TransEnterix by 105.6% in the fourth quarter. Oppenheimer & Co. Inc. now owns 22,000 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 11,300 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of TransEnterix in the fourth quarter worth about $58,000. Great West Life Assurance Co. Can acquired a new stake in shares of TransEnterix in the fourth quarter worth about $70,000. Finally, Annex Advisory Services LLC lifted its position in shares of TransEnterix by 13.1% in the fourth quarter. Annex Advisory Services LLC now owns 34,600 shares of the medical instruments supplier’s stock worth $78,000 after buying an additional 4,000 shares during the last quarter.
In related news, CFO Joseph P. Slattery sold 88,871 shares of the business’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $3.25, for a total transaction of $288,830.75. Following the completion of the transaction, the chief financial officer now owns 44,929 shares of the company’s stock, valued at approximately $146,019.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
TransEnterix (NYSEAMERICAN:TRXC) last announced its quarterly earnings results on Tuesday, February 26th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $7.35 million. The firm’s revenue was up 120.6% on a year-over-year basis.
Separately, Zacks Investment Research cut TransEnterix from a “buy” rating to a “hold” rating in a research report on Friday, January 11th.
TransEnterix Company Profile
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Featured Story: Net Income
Want to see what other hedge funds are holding TRXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransEnterix, Inc. (NYSEAMERICAN:TRXC).
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.